• 1
    Coulie, P. G., Karanikas, V., Colau, D., Lurquin, C., Landry, C., Marchand, M., Dorval, T., Brichard, V. and Boon, T., A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA 2001. 98: 1029010295.
  • 2
    Coulie, P. G., Karanikas, V., Lurquin, C., Colau, D., Connerotte, T., Hanagiri, T., Van Pel, A., Lucas, S., Godelaine, D., Lonchay, C. et al., Cytolytic T cell responses of cancer patients vaccinated with a MAGE antigen. Immunol. Rev. 2002. 188: 3342.
  • 3
    Coulie, P. G. and van der Bruggen, P., T cell responses of vaccinated cancer patients. Curr. Opin. Immunol. 2003. 15: 131137.
  • 4
    Lonchay, C., van der Bruggen, P., Connerotte, T., Hanagiri, T., Coulie, P., Colau, D., Lucas, S., Van Pel, A., Thielemans, K., van Baren, N. and Boon, T., Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. USA 2004. 101: 1463114638.
  • 5
    Schuler-Thurner, B., Schultz, E. S., Berger, T. G., Weinlich, G., Ebner, S., Woerl, P., Bender, A., Feuerstein, B., Fritsch, P. O., Romani, N. and Schuler, G., Rapid induction of tumor-specific type I T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 2002. 195: 12791288.
  • 6
    Phan, G. Q., Touloukian, C. E., Yang, J. C., Restifo, N. P., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Seipp, C. A., Freezer, L. J. et al., Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother. 2003. 26: 349356.
  • 7
    Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J. and Davis, M. M., Phenotypic analysis of antigen-specific T lymphocytes. Science 1996. 274: 9496.
  • 8
    Day, C. L., Seth, N. P., Lucas, M., Appel, H., Gauthier, L., Lauer, G. M., Robbins, G. K., Szczepiorkowski, Z. M., Casson, D. R., Chung, R. T. et al., Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J. Clin. Invest. 2003. 112: 831842.
  • 9
    Meyer, A. L., Trollmo, C., Crawford, F., Marrack, P., Steere, A. C., Huber, B. T., Kappler, J. and Hafler, D. A., Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc. Natl. Acad. Sci. USA 2000. 97: 1143311438.
  • 10
    Danke, N. A. and Kwok, W. W., HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination. J. Immunol. 2003. 171: 31633169.
  • 11
    Lucas, M., Day, C. L., Wyer, J. R., Cunliffe, S. L., Loughry, A., McMichael, A. J. and Klenerman, P., Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells. J. Virol. 2004. 78: 72847287.
  • 12
    Ye, M., Kasey, S., Khurana, S., Nguyen, N. T., Schubert, S., Nugent, C. T., Kuus-Reichel, K. and Hampl, J., MHC class II tetramers containing influenza hemagglutinin and EBV EBNA1 epitopes detect reliably specific CD4(+) T cells in healthy volunteers. Hum. Immunol. 2004. 65: 507513.
  • 13
    Kwok, W. W., Liu, A. W., Novak, E. J., Gebe, J. A., Ettinger, R. A., Nepom, G. T., Reymond, S. N. and Koelle, D. M., HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells. J. Immunol. 2000. 164: 42444249.
  • 14
    Novak, E. J., Liu, A. W., Nepom, G. T. and Kwok, W. W., MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J. Clin. Invest. 1999. 104: R63R67.
  • 15
    Lemaître, F., Viguier, M., Cho, M. S., Fourneau, J. M., Maillère, B., Kourilsky, P., van Endert, P. M. and Ferradini, L., Detection of low-frequency human antigen-specific CD4(+) T cells using MHC class II multimer bead sorting and immunoscope analysis. Eur. J. Immunol. 2004. 34: 29412949.
  • 16
    Schultz, E. S., Lethé, B., Cambiaso, C. L., Van Snick, J., Chaux, P., Corthals, J., Heirman, C., Thielemans, K., Boon, T. and van der Bruggen, P., A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 2000. 60: 62726275.
  • 17
    Malherbe, L., Filippi, C., Julia, V., Foucras, G., Moro, M., Appel, H., Wucherpfennig, K., Guery, J. C. and Glaichenhaus, N., Selective activation and expansion of high-affinity CD4+ T cells in resistant mice upon infection with Leishmania major. Immunity 2000. 13: 771782.
  • 18
    Reichstetter, S., Ettinger, R. A., Liu, A. W., Gebe, J. A., Nepom, G. T. and Kwok, W. W., Distinct T cell interactions with HLA class II tetramers characterize a spectrum of TCR affinities in the human antigen-specific T cell response. J. Immunol. 2000. 165: 69946998.
  • 19
    Schultz, E. S., Schuler-Thurner, B., Stroobant, V., Jenne, L., Berger, T. G., Thielemans, K., van der Bruggen, P. and Schuler, G., Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J. Immunol. 2004. 172: 13041310.
  • 20
    Wang, H. Y., Lee, D. A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E. M. and Wang, R. F., Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004. 20: 107118.
  • 21
    Godelaine, D., Carrasco, J., Lucas, S., Karanikas, V., Schuler-Thurner, B., Coulie, P. G., Schuler, G., Boon, T. and Van Pel, A., Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J. Immunol. 2003. 171: 48934897.
  • 22
    Karanikas, V., Lurquin, C., Colau, D., van Baren, N., De Smet, C., Lethé, B., Connerotte, T., Corbière, V., Demoitié, M.-A., Liénard, D. et al., Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J. Immunol. 2003. 171: 48984904.
  • 23
    Zhang, Y., Chaux, P., Stroobant, V., Eggermont, A. M., Corthals, J., Maillère, B., Thielemans, K., Marchand, M., Boon, T. and van der Bruggen, P., A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J. Immunol. 2003. 171: 219225.
  • 24
    Thurner, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P. et al., Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999. 190: 16691678.
  • 25
    Schuler-Thurner, B., Dieckmann, D., Keikavoussi, P., Bender, A., Maczek, C., Jonuleit, H., Röder, C., Haendle, I., Leisgang, W., Dunbar, R. et al., Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 2000. 165: 34923496.
  • 26
    Scott, C. A., Garcia, K. C., Stura, E. A., Peterson, P. A., Wilson, I. A. and Teyton, L., Engineering protein for X-ray crystallography: the murine major histocompatibility complex class II molecule I-Ad. Protein Sci. 1998. 7: 413418.
  • 27
    Scott, C. A., Garcia, K. C., Carbone, F. R., Wilson, I. A. and Teyton, L., Role of chain pairing for the production of functional soluble IA major histocompatibility complex class II molecules. J. Exp. Med. 1996. 183: 20872095.
  • 28
    Bunch, T. A., Grinblat, Y. and Goldstein, L. S., Characterization and use of the Drosophila metallothionein promoter in cultured Drosophila melanogaster cells. Nucleic Acids Res. 1988. 16: 10431061.
  • 29
    Genevée, C., Diu, A., Nierat, J., Caignard, A., Dietrich, P. Y., Ferradini, L., Roman-Roman, S., Triebel, F. and Hercend, T., An experimentally validated panel of subfamily-specific oligonucleotide primers (Vα1-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 1992. 22: 12611269.